Annals for Hospitalists Inpatient Notes - Clinical Pearls—A Young Man With Lung Cancer and Diarrhea
Authors: David H. Wesorick
Journal: Annals of Internal Medicine (2018)

Web Exclusives21 August 2018Annals for Hospitalists Inpatient Notes - Clinical Pearls—A Young Man With Lung Cancer and DiarrheaDavid H. Wesorick, MDDavid H. Wesorick, MDMichigan Medicine and the Ann Arbor VA Health System, Ann Arbor, Michigan (D.H.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1660 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The patient is a 30-year-old man with metastatic non–small cell lung cancer who presents with diarrhea. The cancer was diagnosed 7 months prior to admission (PTA), with metastases to the brain, liver, and bone. He has been treated with radiation therapy to the brain and the right iliac wing. He also received 6 doses of pembrolizumab (last dose 6 weeks PTA). Reevaluation about 1 month PTA found disease progression, so the treatment regimen was switched to osimertinib. The patient has been receiving this treatment on a daily basis for the past 3 weeks. For the past 2 weeks, he has ...References1. Lamb YN, Scott LJ. Osimertinib: a review in T790M-positive advanced non-small cell lung cancer. Target Oncol. 2017;12:555-62. [PMID: 28710746] doi:10.1007/s11523-017-0519-0 CrossrefMedlineGoogle Scholar2. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-68. [PMID: 29442540] doi:10.1200/JCO.2017.77.6385 CrossrefMedlineGoogle Scholar3. Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018;472:125-33. [PMID: 29143108] doi:10.1007/s00428-017-2267-z CrossrefMedlineGoogle Scholar4. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346-53. [PMID: 27367787] doi:10.1001/jamaoncol.2016.1051 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Michigan Medicine and the Ann Arbor VA Health System, Ann Arbor, Michigan (D.H.W.)Disclosures: Dr. Wesorick has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-1660.Corresponding Author: David H. Wesorick, MD, University of Michigan, 3119 Taubman Center, Box 0376, 1500 East Medical Center Drive, Ann Arbor, MI 48109; e-mail, [email protected]umich.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAnnals for Hospitalists - 21 August 2018 David H. Wesorick and Vineet Chopra Metrics Cited byPembrolizumab 21 August 2018Volume 169, Issue 4Page: HO2-HO3KeywordsBloodBody weightBrainColitisColonDiarrheaFeversHematology and oncologyHospitalistsLung and intrathoracic tumors ePublished: 21 August 2018 Issue Published: 21 August 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...